MOTS-c vs Vilon
Side-by-side comparison of key properties, dosing, and research.
- Summary
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Half-Life
- Estimated 1–2 hours
- Very short as a free dipeptide; effects mediated via gene regulation
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–15 mg
- 1–2 mg SC daily or 5–10 mg oral daily
- Frequency
- 3–5 times per week
- Once daily
- Key Benefits
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Side Effects
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Stacks With
- —
- —